Cited 0 times in
LDL-콜레스테롤 상승 환자에 대한 Atorva-statin의 유효성 및 안전성에 대한 연구
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신민정 | - |
dc.contributor.author | 하종원 | - |
dc.contributor.author | 정남식 | - |
dc.contributor.author | 임세중 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 안신기 | - |
dc.date.accessioned | 2019-11-26T01:08:56Z | - |
dc.date.available | 2019-11-26T01:08:56Z | - |
dc.date.issued | 1999 | - |
dc.identifier.issn | 1738-5520 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/172780 | - |
dc.description.abstract | Background and Objectives : HMG-CoA reductase inhibitors have been used for a decade to lower LDL cholesterol levels and to improve cardiovascular diseases and clinical outcomes. This study was designed to evaluate the clinical efficacy and safety profiles of atorvastatin, a new HMG-CoA reductase inhibitor, in patients with elevated LDL-cholesterolemia. Material and Methods : Eighty three patients who had high 12-hour fasting serum LDL-cholesterol level (≥145 mg/dl and ≤ 250 mg/dl) and serum TG level less than 400 mg/dl were enrolled. After completing an 4 week dietary phase, 50 patients who still had LDL-C ≥145 mg/dl and TG ≤400 mg/dl were assigned to receive atorvastatin 10 mg once daily for 4 weeks. After 4 weeks, the dose was continued for 4 weeks in each individual if serum LDL-cholesterol was maintained below 130 mg/dL. For each individual whose serum LDL-cholesterol was above 130 mg/dL, the dose was doubled (20 mg/day) and administered for 4 weeks. Serum AST, ALT and CPK were also measured in addition to blood chemistry tests for lipid profiles at 4 and 8 weeks for safety assessment. Results : 1) The total study population who completed the whole protocol was composed of 46 patients (23 male, 23 female, mean age 54 years). 2) At 4 weeks, the reduction by mean percent change from the baseline in LDL-cholesterol was -44.8% (from 182.3±3.4 mg/dl to 99.7±2.9 mg/dl). The fixed goal of LDL-cholesterol less than 130 mg/dl was achieved by 95.8%. 3) At 4 weeks, the mean percent change from the baseline in TC, TG, HDL-C, LDL/HDL-C and ApoB were -32.3%, -17.4%, +9.6%, -48.5% and -36.6%, respectively. 4) At 8 weeks, the mean percent change from the baseline in LDL-cholesterol was -43.0% (from 182.3±3.4 mg/dl to 103±2.4 mg/dl). The fixed goal of LDL-cholesterol less than 130 mg/dl was achieved by 91.3% of the whole patients. 5) At 8 weeks, the mean percent change from the baseline in TC, TG, HDL-C, LDL/HDL-C and ApoB were -31.3%, -22.6%, +13.7%, -48.8% and -35.9%, respectively. 6) No serious side effects were observed during the whole period. Conclusion : Atorvastatin is highly effective and safe in modulating lipid profiles favorably (lower LDL-Cholesterol, lower TG, elevate HDL-Cholesterol), in patients with serum lipid abnormality. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | Korean | - |
dc.publisher | 대한심장학회 | - |
dc.relation.isPartOf | Korean Circulation Journal (순환기) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | LDL-콜레스테롤 상승 환자에 대한 Atorva-statin의 유효성 및 안전성에 대한 연구 | - |
dc.title.alternative | Efficacy and Safety of Atorvastatin in Patients with Elevated LDL-cholesterolemia | - |
dc.type | Article | - |
dc.contributor.college | Research Institutes (연구소) | - |
dc.contributor.department | Yonsei Cardiovascular Research Institute (심혈관연구소) | - |
dc.contributor.googleauthor | 전국진 | - |
dc.contributor.googleauthor | 정남식 | - |
dc.contributor.googleauthor | 안신기 | - |
dc.contributor.googleauthor | 하종원 | - |
dc.contributor.googleauthor | 임세중 | - |
dc.contributor.googleauthor | 장양수 | - |
dc.contributor.googleauthor | 심원흠 | - |
dc.contributor.googleauthor | 조승연 | - |
dc.contributor.googleauthor | 김성순 | - |
dc.contributor.googleauthor | 이선호 | - |
dc.contributor.googleauthor | 신민정 | - |
dc.identifier.doi | 10.4070/kcj.1999.29.12.1309 | - |
dc.contributor.localId | A02103 | - |
dc.contributor.localId | A04257 | - |
dc.relation.journalcode | J01953 | - |
dc.identifier.eissn | 1738-5555 | - |
dc.subject.keyword | Atorvastatin | - |
dc.subject.keyword | LDL cholesterol | - |
dc.subject.keyword | Hypercholesterolemia | - |
dc.contributor.alternativeName | Shin, Min Jeong | - |
dc.contributor.affiliatedAuthor | 신민정 | - |
dc.contributor.affiliatedAuthor | 하종원 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1309 | - |
dc.citation.endPage | 1316 | - |
dc.identifier.bibliographicCitation | Korean Circulation Journal (순환기), Vol.29(12) : 1309-1316, 1999 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.